Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Fengcai Zhu and Xiling Guo.
Fengcai Zhu
Connection Strength
0.647
Xiling Guo
  1. Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials. Signal Transduct Target Ther. 2021 07 15; 6(1):271.
    View in: PubMed
    Score: 0.239
  2. Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med. 2021 06; 27(6):1062-1070.
    View in: PubMed
    Score: 0.235
  3. An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. Signal Transduct Target Ther. 2021 04 24; 6(1):165.
    View in: PubMed
    Score: 0.059
  4. HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV. J Virol. 2021 01 28; 95(4).
    View in: PubMed
    Score: 0.058
  5. Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China. J Infect Dis. 2020 08 04; 222(5):746-754.
    View in: PubMed
    Score: 0.056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.